The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A Phase I, Randomised, double blind, placebo controlled, 2-part study to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses of AZD9668 in healthy volunteers
- collapse A randomised, double blind, placebo controlled, parallell group, phase 1 study to assess the safety, tolerability and pharmacokinetics of single and mutlitple ascending oral doses of AZD9668 in healthy japanese and caucasion volunteers
- collapse A 2-week, randomised, double-blind, placebo-controlled, parallel group study to assess the tolerability and pharmacokinetics of orally administered AZD9668 in patients with COPD
- collapse A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients
- collapse A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered via Single Inhalation Device Compared to AZD3199 Administered via Turbuhaler™1 Inhaler in Patients With Asthma
- collapse Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation for Long-term Use in Pediatrics
- collapse A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 μg and 1200 µg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
- collapse A phase I, randomised, double-blind, placebo-controlled, parallel-group, single-centre study to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of AZD3199 given once daily as inhaled formulation via Turbuhaler to Japanese healthy men
- collapse A phase I, randomised, double-blind, placebo-controlled, parallel-group, single-centre study to investigate the safety, tolerability and pharmacokinetics of multiple ascending doses of AZD3199 (a β2-agonist ) given once daily as inhaled formulation via Turbuhaler to healthy men
- collapse A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 µg formoterol bid and placebo in patients with moderate to severe COPD
